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Abstract
Background: Cerebral infarction frequently leads to mild cognitive impairment (MCI). Prompt management of MCI
can prevent vascular dementia and improve patient outcome. This single center randomized controlled trial aims to
investigate the efficacy and safety of acupuncture and nimodipine to treat post-cerebral infarction MCI.
Methods: A total of 126 Chinese patients with post-cerebral infarction MCI recruited from the First Teaching
Hospital of Tianjin University of Traditional Chinese Medicine between April 2013 and June 2014 were randomized
at 1:1: 1 ratio into nimodipine alone (30 mg/time and 3 times daily), acupuncture alone (30 min/time, 6 times/
week), and nimodipine + acupuncture groups. The treatments were 3 months. Cognitive function was evaluated
using Montreal Cognitive Assessment (MoCA) scale at enrollment interview, at the end of 3-month therapy, and at
the post-treatment 3-month follow-up.
Results: The per-protocol set included 39, 40, and 40 patients from nimodipine alone, acupuncture alone, and the
combination group, respectively, was analyzed. Intra-group comparison revealed that MoCA score at the follow-up
improved significantly by 15.8 ± 10.9, 20.9 ± 13.8 %, and 30.2 ± 19.7 % compared with the baseline MoCA for
nimodipine alone, acupuncture alone, and the combination group, respectively. Inter-group comparison
demonstrated that the combination therapy improved MoCA score (5.5 ± 2.2) at significantly higher extent
than nimodipine alone (3.1 ± 1.8) and acupuncture alone (4.3 ± 2.3) at the follow-up (All P < 0.05), and significantly
higher proportion of patients in acupuncture alone group (80 %) and the combination therapy group (90 %) than in
nimodipine alone group (56.4 %) showed ≥12 % MoCA score improvement compared with the baseline MoCA
(All P < 0.05). No adverse event was reported during the study.
Conclusion: Acupuncture may be used as an additional therapy to conventional pharmacological treatment
to further improve the clinical outcomes of patients with post-cerebral infarction MCI.
Trial registration: The study was registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/,
Unique Identifier: ChiCTR-IOR-15007366). The date of registration is November 4, 2015.
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Background
Cerebrovascular disease such as stroke often causes
cognitive dysfunction ranging from mild cognitive
impairment (MCI) to dementia. The prevalence of
post-stroke cognitive impairment has been reported
to be 20–80 % in patients with different nationality
and races according to different diagnostic criteria
[1]. Approximately 23–30 % of patients with stroke
will develop MCI or dementia within 4 years after
the stroke [2].
Management of post-stroke cognitive impairment
has not been standardized. Previous clinical trials have
shown that drugs that are usually used to treat
Alzheimer’s disease, such as the cholinesterase inhibi-
tors donepezil, galantamine, and rivastigmine, and the
noncompetitive N-methyl-D-aspartate receptor antag-
onist memantine, were associated with neurological
benefits in patients with post-stroke cognitive impair-
ment [3–9]. However, because of uncertain effect of
the drugs on global and daily function, none of the
drugs has achieved regulatory approval for the treat-
ment of vascular cognitive impairment (VCI) [10].
Nimodipine, which is a 1,4-dihydropyridine-derivative
calcium channel blocker, can reduce the severity of ar-
terial spasm-induced ischemic neurologic deficits when
it is administered within 96 h of the onset of subarach-
noid hemorrhage [11]. Recent clinical studies further
support its beneficial effects on neurological outcomes
in patients with subarachnoid hemorrhage [12]. In a
systematic review of double-blinded randomized trials,
nimodipine was found to have short-term benefit in
terms of clinical global impression and cognitive
function but not of activities of daily living in patients
with VCI [13]. Although the efficacy of nimodipine in
dementia, such as Alzheimer’s disease and VCI, is still
uncertain, it is currently commonly used for VCI and
dementia in China and several continental European
countries.
In addition to the pharmacological therapies, acu-
puncture has also been explored to treat VCI [14]. A
recent systematic meta-analysis including 691 partici-
pants pooled from 12 randomized controlled trials has
shown that combination therapy of acupuncture plus
other conventional therapy improved mini-mental
state examination (MMSE) score significantly in
patients with vascular MCI [14]. However, all the
included clinical trials appear to have low quality in
methodology and high risk of bias [14]. Here, this
study aims to conduct a randomized trial including
126 patients with post-stroke MCI to compare the
efficacy of combination therapy of acupuncture plus
nimodipine versus acupuncture alone and nimodipine
alone. Montreal Cognitive Assessment (MoCA) scor-
ing system was used to evaluate the patient outcomes.
Methods
Trial design
This single center randomized controlled trial with 1:1:1
allocation was conducted in the First Teaching Hospital
of Tianjin University of Traditional Chinese Medicine
from April 2013 to June 2014. This trial was conducted
in accordance with the principles of the Declaration of
Helsinki. The study protocol has been approved by the
Institutional Review Board of Tianjin University of
Traditional Chinese Medicine (No. TYLL2013 [K] 002).
The study was registered at the Chinese Clinical Trial
Registry (http://www.chictr.org/cn, Unique Identifier: Ch
iCTR-IOR-15007366). Written informed consent was
obtained from all patients.
Patients
Patients that met all of the following inclusion criteria
were enrolled: 1) aged 50 to 80 years; 2) a confirmed
history of cerebrovascular ischemia based on the results
from cerebral perfusion computed tomography or
magnetic resonance imaging; 3) a recent episode of cere-
bral infarction that occurred 0.5 to 6 months prior to
the enrollment interview; 4) a Modified Ashworth Scale
score of muscle tone ≥ 3; 5) no severe language and cog-
nitive disorder but presenting MCI with a MoCA score
< 26; [15] the definition of MCI in this study was that
the cognitive impairment was not severe enough to
interfere with everyday life; [16] 6) was literate and able
to read and understand the informed consent form; 7)
voluntarily signed the informed consent form. Patients
that met any one of the following exclusion criteria were
excluded: 1) transient ischemic attack; 2) presenting
cerebral hemorrhage or other disease-associated cogni-
tive impairment; 3) severe hearing, vision, and/or cogni-
tive dysfunction; 4) a history of mental disease; 5) severe
diseases in the internal organs, including the heart, liver,
and kidney; 6) allergic to the study drug; 7) acupuncture
syncope; 8) were taking medications that may interfere
in the efficacy assessment of the study therapies, includ-
ing nimodipine, citicoline sodium capsules, and/or nicer-
goline tablets at the time of the enrollment interview or
within 30 days before the enrollment interview.
Randomization, allocation, and blinding
Eligible patients were randomized into the following 3
groups at 1:1:1 ratio: nimodipine alone, acupuncture
alone, nimodipine and acupuncture. The patient allocation
sequence was generated using a complete randomization
procedure. The random number and the associated
allocated treatment were kept in sequentially numbered
sealed opaque envelopes. The person that generated the
randomization sequence was not a participating inve-
stigator and not involved in patient enrollment and ass-
essment. In this trial, patients were not blinded for the
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treatment allocation. Physicians that prescribed the study
medication and acupuncture therapy were not blinded for
the treatment allocation. Both the trained assessor, who
evaluated patient MoCA score, and the statistician, who
conducted the data analysis, were blinded to the treatment
allocation. The treatment allocation was exposed to the
participating investigators after the completion of data
analysis.
Interventions
During the study, eligible patients were permitted to
continue their existing medications, including drugs to
inhibit platelet aggregation, lipid-lowering drugs, anti-
hypertensive drugs, and hypoglycemic agents. Patients
were required to document the medication use in
details. Eligible patients were treated with one of the
following 3 therapies: nimodipine tablet (Bayer health-
care company, H20003010, 30 mg per tablet) alone,
acupuncture alone, and nimodipine + acupuncture.
The dosage of the nimodipine therapy was one tablet
per time and 3 times daily for 3 months. The dosage
of acupuncture therapy was one 30-min acupuncture
section daily 6 days per week from Monday to Saturday
for 3 months [17–19]. Disposable sterile acupuncture
needles (Brand name: Hua Tuo, size: 0.25 × 40 mm,
Suzhou Medical instruments Co., Ltd, China) were
used. A total of 12 acupoints were treated in the
acupuncture therapy, including Baihui (DU20),
Sishencong (EX-HN1), Sibai (ST2), Fengchi (GB20),
Wangu (GB12), Tianzhu (BL10), Renzhong (DU26),
Shenmen (HT7), Neiguan (PC6), Fenglong (ST40),
Sanyinjiao (SP6), and Taichong (LR3) [20, 21]. The
skin areas of the acupoints were sterilized by a wipe
with 75 % ethanol.
Distinct acupuncture needling technique was applied
on different acupoints. Horizontal insertion with one
Chinese cun (approximately 3.3 cm) in depth was
applied on Baihui (DU20) and Sishencong (EX-HN1).
Oblique insertion was used for the acupoint Sibai (ST2)
and the needled was inserted 0.5 cun (approximately
1.65 cm) in depth. The needles in the 3 acupoints were
twirled gently for 30 s. At the acupoints Fengchi (GB20),
Wangu (GB12), and Tianzhu (BL10), vertical insertion
with a 1 to 1.5 cun (3.3 to 4.95 cm) in depth was used
and the needles were also twirled gently for 30 s. A nee-
dle was inserted obliquely with 0.3 to 0.5 cun in depth
toward the nasal septum at Renzhong (DU26), and heavy
bird-pecking needling was applied until tear formation
was observed in patients’ eyes. Vertical insertion with a
depth of 0.5 to 1 cun was applied at Neiguan (PC6), and
the needle was twirled, lifted, and thrust gently for one mi-
nute. At Shenmen (HT7) and Sanyinjiao (SP6), needles
were inserted vertically with a depth of 0.2–0.5 cun and
0.5–1.0 cun, respectively. The needles were twirled gently
30 s. Needles were inserted vertically with a depth of 1.0 to
1.5 cun at Fenglong (ST40) and Taichong (LR3), and the
needles were twirled, lifted, and thrust gently for one mi-
nute. Needles were kept in all of the acupoints for 30 min.
Outcome assessment
Patients’ cognitive function was assessed by the
MoCA test, and MoCA score was used to evaluate
the efficacy of the therapies. The MoCA test and the
instructions in Chinese are available for download
from the following official website of the Montreal
Cognitive Assessment: http://www.mocatest.org/wp-
content/uploads/2015/tests-instructions. The MoCA
test is displayed in Additional file 1: Table S1. Trained as-
sessors evaluated patients’ MoCA score at the enrollment
interview, at the end of the 3-month therapy, and at the 3-
month post-treatment follow-up. The efficacy index was
calculated based on the following equation: (post-treat-
ment or follow-up MoCA score – baseline MoCA score)
÷ baseline MoCA score × 100 %. Efficacy index ≥12 % was
considered effective response and <12 % was considered
ineffective response.
Adverse events
Adverse events (AEs) that may or may not be associated
with the study therapies, including abnormal gastrointes-
tinal reactions, cardiovascular events, allergic reactions,
and other medical conditions were recorded.
Sample size determination
Previous studies have shown that the rate of effective
response was approximately 60 % and 80 % in patients
with MCI receiving nimodipine alone and acupuncture
alone, respectively [17]. We assumed that the rate of
effective response to combination of nimodipine and
acupuncture would be ≥ 85 %. Under the assumption of
a significant level of 0.05 (one-side), 80 % power, and
15 % data loss, a total of 120 patients were required.
Thus, 126 patients (42 patients in each group) were
enrolled in this study.
Statistical analysis
Patients that had poor compliance to the study protocol,
failed to come back to the follow-up, or developed severe
adverse reactions were removed from the analysis. Per-
protocol (PP) dataset was used for statistical analysis.
Continuous variables are presented as mean ± standard
deviation (SD). Count variables are presented as number
of cases or percentage. One-way ANOVA was used to
compare baseline BMI, and Kruskal-Wallis rank sum test
was used to compare age, sex distribution, and MoCA
baseline score. For intra-group comparison of MoCA
score improvement at the end of 3-month therapy versus
that at the follow-up, Kruskal-Wallis rank sum test was
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used for the acupuncture alone group; independent sam-
ple t-test was used for the nimodipine alone and nimodi-
pine + acupuncture groups. Kruskal-Wallis rank sum test
was used for comparison of percentage improvement of
MoCA score at the end of 3-month therapy versus that at
the follow-up in each group. Kruskal-Wallis rank sum test
was used for inter-group comparison of MoCA score
improvement; Nemenyi test was used for 2-group compari-
son. Pearson chi-square test was used to compare the pro-
portion of effective response of the 3 groups. The statistical
analysis software SPSS 18.0 was used. P value was 2-sided
and P < 0.05 was considered significantly different.
Results
Baseline data
A total of 126 patients were recruited from April 2013
to June 2014 and randomized into the 3 groups (42
patients per group). After the 3-month post-treatment
follow-up, data of 39, 40, and 40 patients from nimodi-
pine alone, acupuncture alone, and nimodipine + acu-
puncture group, respectively were analyzed. Thus, the
PP dataset included 119 patients, and the dropout rate
was 5.6 % (7/126). The CONSORT flow diagram is
displayed in Fig. 1b. Baseline data showed that sex distri-
bution and body mass index were comparable in the 3
groups (Table 1). However, age was significantly different
among the 3 groups (P = 0.021), and patients in the
nimodipine alone group appeared to have younger
mean age than patients in acupuncture alone and
acupuncture + nimodipine group (Table 1). The baseline
MoCA score was not significantly different among the 3
groups (P = 0.242, Table 1).
Efficacy assessment
In each group, the mean MoCA score increased signifi-
cantly at the end of 3-month treatment compared with
the baseline values (All P < 0.05, Table 2), and further
increased and remained at a significantly higher level
at the 3-month follow-up (All P < 0.05, Table 2). The
mean percentage MoCA improvement at the follow-up
was higher than that at the end of 3-month treatment
Fig. 1 CONSORT patient flow diagram













60.6 (6.7) 64.4 (7.7) 65.2 (7.1) 0.021
BMI, mean (SD) 23.2 (2.2) 24.2 (2.2) 23.9 (2.9) 0.220
Men, n (%) 26 (66.7) 30 (75.0) 26 (65.0) 0.584
HDL (mmol/L),
mean (SD)
1.1 (0.2) 1.1 (0.3) 1.1 (0.2)
LDL (mmol/L),
mean (SD)








6.2 (2.1) 5.7 (2.0) 5.7 (2.0)
MoCA
Mean (SD) 21.1 (4.3) 21.8 (3.5) 20.5 (3.9) 0.242
Median 22 22 22
Min, Max 7, 26 10, 25 11, 25
SD standard deviation, BMI body mass index, HDL high-density lipoprotein,
LDL, low-density lipoprotein
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in each group (Table 2). Particularly, in the combin-
ation therapy group, the percentage MoCA score im-
provement at follow-up was significantly higher than
that at the end of the combination therapy (P = 0.037,
Table 2). These data suggest that all 3 therapies may
improve cognitive function and the improvement ap-
pear to be enhanced and sustained at least for 3 months
after the therapies.
The actual MoCA scores at follow-up of the acupuncture
alone group (26.1 ± 3.6, P = 0.043) and nimodipine + acu-
puncture groups (26.0 ± 2.8, P = 0.034) were significantly
higher than that of the nimodipine alone group (24.2 ± 4.6,
Fig. 2a). However, the MoCA scores at the end of 3-month
therapy were not significantly different in the three patient
groups (Fig. 2a). Inter-group comparison revealed that the
mean MoCA score improvement after 3-month acupunc-
ture alone (3.6 ± 2.4) was higher than that after 3-month
nimodipine alone treatment (2.4 ± 2.1) although the
difference was not statistically significant (P = 0.091, Fig. 2b).
In contrast, The MoCA score improvement after 3-month
combination therapy (4.0 ± 2.0) was significantly greater
than that after nimodipine alone treatment (P = 0.002,
Fig. 2b). At the post-treatment 3-month follow-up, the
MoCA score improvement in acupuncture alone (4.3 ± 2.3)
was not significantly different from that (3.1 ± 1.8) in nimo-
dipine alone group (P = 0.070, Fig. 2b). However, the
MoCA score improvement at the post-treatment 3-month
follow-up in the combination therapy group (5.5 ± 2.2)
was significantly higher than both acupuncture alone
(P = 0.042) and nimodipine alone (P < 0.0001, Fig. 2b)
groups. Thus, the combination therapy of nimodipine
and acupuncture appears to have superior efficacy on
post-cerebral infarction MCI to nimodipine monotherapy
and acupuncture monotherapy.
In addition, at the end of 3-month treatment, signifi-
cantly higher proportion of patients in the combination
therapy group (77.5 %) showed effective response
(≥12 % increase in MoCA score compared with the
baseline MoCA) than the nimodipine alone group
(46.2 %, P = 0.004, Fig. 2c). At the post-treatment 3-month
follow-up, the proportion of patients that showed effective
response increased to 80 % and 90 % for the acupuncture
alone group and the combination therapy group,
respectively, and these values were significantly higher
than that in the nimodipine alone group (56.4 %, all
P < 0.05, Fig. 2c). No AE was reported during the study.
The original data are presented in the Additional file 2:
Table S2.
Discussion
In this randomized controlled clinical trial, 3-month
nimodipine monotherapy, acupuncture monotherapy,
and combination therapy of nimodipine plus acupunc-
ture improved cognitive function significantly in patients
with post-cerebral infarction MCI, and the cognitive
improvement was sustained and even became more
apparent 3 months after the treatments. Notable,
compared with the monotherapies, the combination
therapy was associated the best cognitive improvement,
suggesting that nimodipine and acupuncture may result
in additive neurological benefit in patients with post-
cerebral infarction MCI.
These findings are consistent with the results from previ-
ous trials assessing the therapeutic value of acupuncture in
cognitive impairment. Our previous clinical trial showed
that MoCA score improvement after 3-month combination
therapy of nimodipine plus acupuncture was 1.88 folds of
that after nimodipine monotherapy group [22]. Similarly,
this current study found that the MoCA score improve-
ment in the combination therapy group was 1.66 folds of
that in the nimodipine monotherapy group at the end of
the treatment and further increased to 1.77 folds at post-
treatment 3-month follow-up. Different types of acupunc-
ture, such as electroacupuncture and body acupuncture,
different types of conventional therapy, including nimodi-
pine, donepezil, and cognitive function training, and various
efficacy evaluation system, such as MoCA, Mini-Mental
State Examination (MMSE), Modified Barthel Index, and
Wechsler Memory Scale have been used in clinical trials to
compare the efficacy of combination of acupuncture plus
conventional therapy versus conventional therapy alone in
patients with vascular MCI. Cao et al. conducted a meta-
analysis on 12 randomized controlled trials and found that
combination therapy consistently showed superior effi-
cacy on cognitive improvement to conventional therap-
ies regardless of the types of acupuncture therapy,
Table 2 Intra-group comparison of the effect of the therapies on MoCA score
Nimodipine alone Acupuncture alone Nimodipine + Acupuncture
n = 39, Mean (SD) n = 40, Mean (SD) n = 40, Mean (SD)
MoCA Increase % MoCA Increase % MoCA Increase %
Baseline 21.1 (4.3) n/a n/a 21.8 (3.5) n/a n/a 20.5 (3.9) n/a n/a
After treatment 23.5 (4.6)a 2.4 (2.1) 12.7 (14.1) 25.4 (4.1)a 3.6 (2.4) 16.8 (13.1) 24.5 (3.3)a 4.0 (2.0)b 21.6 (14.3)c
At follow-up 24.2 (4.6)a 3.1 (1.8) 15.8 (10.9) 26.1 (3.6)a 4.3 (2.3) 20.9 (13.8) 26.0 (2.8)a 5.5 (2.2)b 30.2 (19.7)c
MoCA score increase was calculated as: MoCA score at the end of the therapy or at the follow-up – baseline MoCA score. MoCA % increase was calculated as:
MoCA score increase ÷ baseline MoCA score × 100 %. arepresents significant different between the indicated score vs. the baseline MoCA score in each group.
brepresents significant different between the indicated values (P = 0.002). crepresents significantly different between the indicated values (P = 0.037)
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conventional therapy, and efficacy evaluation system
that were used in the trials although most of the in-
cluded studies suffered poor quality in methodology
and high risk of bias [14]. This conclusion is further
supported by a more recent meta-analysis that com-
pared the efficacy of combination of acupuncture plus
conventional therapy versus conventional therapy alone
in patients with post-stroke cognitive impairment [23].
In this current study, the improvement in MoCA score
after acupuncture monotherapy was higher than that
after nimodipine monotherapy although the difference
was not statistically significant. However, significantly
higher proportion of patients achieved ≥12 % increase in
MoCA score after acupuncture monotherapy than after
nimodipine monotherapy. These findings suggest that
acupuncture may be more effective than nimodipine in
patients with post-cerebral infarction MCI. Similarly,
previous studies have demonstrated that both electroa-
cupuncture and body acupuncture monotherapy im-
proved MMSE score or MoCA score at significantly
higher extent than nimodipine alone [14, 24].
The molecular and cellular mechanism underlying the
beneficial effect of acupuncture on neurological outcome
has been investigated in animal models. Lee et al. used
scopolamine to induce cognitive impairment in rats and
found that acupuncture stimulation at Baihui (DU20)
acupoint improved rat memory significantly and re-
stored the mRNA expression of molecules that are in-
volved in memory function in hippocampus such as
cAMP-response element-binding protein (CREB) [25].
Similarly, Li et al. also found that acupuncture increased
the expression of CREB and phosphorylated CREB and
improved memory function in rats with vascular dementia
induced by homologous blood clot emboli [26]. Further-
more, acupuncture has been shown to significantly in-
crease the number of neurons in the hippocampal CA1
area of rats with vascular dementia [27, 28]. Magnetic
resonance imaging (MRI) revealed that acupuncture acti-
vated neurons in cognitive-related cortical area in patients
with MCI [29–31]. These preclinical and clinical studies
indicate that acupuncture may improve cognitive function
by activating neurons, reversing brain damage-associated
alteration of molecules, such as the CREB pathway, and
increasing the number of neurons in hippocampus.
There are several limitations in this study. Only MoCA
scale was used to assess the cognitive function in this
current study. Although compared with comprehensive
neuropsychological battery, MoCA is short and has good
sensitive and specificity to MCI, additional evaluation test
such as Addenbrooke’s Cognitive Examination–Revised
would improve the evaluation accuracy [15]. The duration
of acupuncture therapy and follow-up time in this current
study was only 3 months, respectively. Long-term effect of
acupuncture on vascular MCI remains unknown. More-
over, patients in the acupuncture alone and the combin-
ation therapy groups were significantly older than patients
in the nimodipine alone group. This non-uniform age
distribution may be associated with the small sample size
and single center nature of this current study. Thus, multi-
center large-scale studies with better randomization
Fig. 2 Comparison of MoCA score improvement and proportion of
effective response of the 3 groups. a MoCA scores of the three patient
groups. b Comparison of MoCA score improvement of the 3 groups.
Kruskal-Wallis rank sum test was used to compare the 3 groups; Nemenyi
test was used for 2-group comparison. c Comparison of the proportion
of effective response of the 3 groups. Pearson chi-square test was used.
*represent significant difference, and P< 0.05 was considered statistically
significantly different
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scheme and comprehensive efficacy evaluation method are
required to further verify the conclusion. Furthermore, the
improvements across the therapies in the current study
could be partially attributable to a spontaneous recovery. A
placebo control group, in which patients received no treat-
ments, would be necessary to investigate the spontaneous
recovery. However, because the participating patients were
likely in a critical therapeutic window (0.5 to 6 months
post-infarction) for effective interventions to attenuate the
MCI and the potential risk of a deterioration of the MCI if
left untreated may be high, inclusion of a placebo control
group in the current prospective randomized controlled
trial may highly likely be disapproved by the Institutional
Review Board. In addition, even if a spontaneous recovery
existed, it would theoretically affect the three patient group
equally because of the randomized design in the current
study. Thus, we did not include such placebo control.
Certainly, the current study cannot exclude the possibility
that some patients with post-cerebral infarction MCI may
recover spontaneously. Spontaneous recovery from post-
stroke cognitive impairment has been reported previously
[32–37]. Rasquin et al. followed up 118 patients with a first
ever cerebral stroke for 2 years, and they found that 20.3 %
of the patients had reversible MCI and most of the recov-
ery occurred between one-month and 6-month post-
stroke [37]. They also discovered that higher baseline
MMSE scores, which was determined at post-stroke
one month, and female sex were independent predic-
tors of the recovery [37].
Conclusions
The findings of this current study suggest that acupunc-
ture may be used as an additional therapy to conven-
tional pharmacological treatment to further improve the
clinical outcomes of patients with post-cerebral infarc-
tion MCI. Long-term and large scaled studies with more
comprehensive efficacy evaluation system are still re-
quired to further verify the conclusion.
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